Know Cancer

or
forgot password


Phase 3
16 Years
75 Years
Not Enrolling
Both
Hodgkin´s Lymphoma

Thank you

Trial Information


Inclusion Criteria:



- Hodgkin´s lymphoma (histologically proven)

- CS (PS) IA, IB, IIA,IIB without any of the following risk factors:

1. bulky mediastinal mass (> 1/3 maximum transverse thorax diameter)

2. extranodal involvement

3. ESR > 50 (A), > 30 (B-symptoms)

4. 3 or more lymph node areas involved

- written informaed consent

Exclusion Criteria:

- Leukocytes <3000/microl

- Platelets <100000/microl

- Hodgkin´s Disease as "composite lymphoma"

- Activity index (WHO) < grade 2

Type of Study:

Interventional

Study Design:

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Progression free survival (PFS)

Outcome Time Frame:

5 years

Safety Issue:

No

Principal Investigator

Volker Diehl, Prof.

Investigator Role:

Principal Investigator

Investigator Affiliation:

University of Cologne

Authority:

Germany: Federal Institute for Drugs and Medical Devices

Study ID:

HD10

NCT ID:

NCT00265018

Start Date:

May 1998

Completion Date:

Related Keywords:

  • Hodgkin´s Lymphoma
  • Hodgkin´s lymphoma
  • early stages
  • Hodgkin Disease
  • Lymphoma

Name

Location